DWP
OCUL icon

Daymark Wealth Partners’s Ocular Therapeutix OCUL Stock Holding History

Daymark Wealth Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,000
Closed -$103K – 524
2024
Q2 		$103K Hold
15,000
– – ﹤0.01% 489
2024
Q1 		$137K Sell
15,000
-10,000
-40% -$71K 0.01% 422
2023
Q4 		$112K Hold
25,000
– – 0.01% 394
2023
Q3 		$78.5K Hold
25,000
– – 0.01% 373
2023
Q2 		$129K Buy
+25,000
New +$149K 0.01% 368

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Daymark Wealth Partners's OCUL Position: Q3 2024 in Review

Daymark Wealth Partners sold out of Ocular Therapeutix (OCUL) in Q3 2024, closing a stake of 15,000 shares — an estimated $103K sold.

Daymark Wealth Partners first reported a position in OCUL in Q2 2023 and held it in 5 quarters. The position peaked at $137K in Q1 2024. 168 funds tracked by Wall St. Rank hold OCUL as of Q3 2024.

  • Daymark Wealth Partners reported no remaining Ocular Therapeutix position as of Q3 2024 after selling out during the quarter.
  • Daymark Wealth Partners sold 15,000 Ocular Therapeutix shares in Q3 2024, an estimated $103K.
  • Daymark Wealth Partners first reported a position in Ocular Therapeutix in Q2 2023 and held it in 5 quarters.
  • Daymark Wealth Partners's Ocular Therapeutix position peaked at $137K in Q1 2024.
  • 168 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2024.

Based on Daymark Wealth Partners's 13F filing for Q3 2024, filed 8 Oct 2024.